ExodusPoint Capital Management LP grew its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 1.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,164 shares of the biotechnology company’s stock after purchasing an additional 348 shares during the period. ExodusPoint Capital Management LP owned approximately 0.11% of Arcturus Therapeutics worth $723,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in ARCT. Daiwa Securities Group Inc. grew its stake in Arcturus Therapeutics by 23.8% during the 1st quarter. Daiwa Securities Group Inc. now owns 4,109 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 789 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Arcturus Therapeutics during the first quarter worth approximately $103,000. Point72 Middle East FZE bought a new stake in shares of Arcturus Therapeutics in the fourth quarter worth $79,000. Allspring Global Investments Holdings LLC raised its holdings in Arcturus Therapeutics by 162.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 4,786 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 2,961 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in Arcturus Therapeutics by 63.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 1,956 shares during the last quarter. 88.87% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Arcturus Therapeutics news, COO Pad Chivukula sold 25,000 shares of the business’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $35.01, for a total transaction of $875,250.00. Following the completion of the transaction, the chief operating officer now owns 519,448 shares in the company, valued at approximately $18,185,874.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Arcturus Therapeutics news, COO Pad Chivukula sold 25,000 shares of the business’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $35.01, for a total transaction of $875,250.00. Following the sale, the chief operating officer now directly owns 519,448 shares in the company, valued at approximately $18,185,874.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Keith C. Kummerfeld sold 6,968 shares of the stock in a transaction on Friday, July 14th. The shares were sold at an average price of $35.00, for a total value of $243,880.00. Following the transaction, the insider now directly owns 950 shares of the company’s stock, valued at $33,250. The disclosure for this sale can be found here. Insiders sold 41,968 shares of company stock valued at $1,420,130 in the last three months. 13.80% of the stock is currently owned by corporate insiders.
Arcturus Therapeutics Stock Performance
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.98) EPS for the quarter, missing the consensus estimate of $0.09 by ($2.07). Arcturus Therapeutics had a net margin of 30.36% and a return on equity of 20.75%. The firm had revenue of $10.52 million during the quarter, compared to analyst estimates of $71.05 million. Analysts predict that Arcturus Therapeutics Holdings Inc. will post -3.56 EPS for the current year.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on ARCT. Guggenheim reissued a “buy” rating on shares of Arcturus Therapeutics in a research report on Friday, July 14th. StockNews.com began coverage on Arcturus Therapeutics in a research note on Thursday, August 17th. They set a “hold” rating on the stock. William Blair initiated coverage on Arcturus Therapeutics in a research report on Monday, July 24th. They issued an “outperform” rating and a $71.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $51.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday. Finally, Wells Fargo & Company raised their price objective on Arcturus Therapeutics from $35.00 to $45.00 in a research note on Monday, July 17th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $38.78.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
- Five stocks we like better than Arcturus Therapeutics
- Best Stocks Under $5.00
- These Quality Dividend Kings Grow their Dividends the Fastest
- What Does the Consumer Price Index Measure?
- 3 Growth Stocks to Buy in September
- What is the Death Cross and How Can Investors Use it For Successful Trading?
- 3 Underappreciated Stocks with Nowhere to Go But Up
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.